» Articles » PMID: 39287860

Insulin Resistance, Obesity, and Lipotoxicity

Overview
Date 2024 Sep 17
PMID 39287860
Authors
Affiliations
Soon will be listed here.
Abstract

Lipotoxicity, originally used to describe the destructive effects of excess fat accumulation on glucose metabolism, causes functional impairments in several metabolic pathways, both in adipose tissue and peripheral organs, like liver, heart, pancreas, and muscle. Ectopic lipid accumulation in the kidneys, liver, and heart has important clinical counterparts like diabetic nephropathy in type 2 diabetes mellitus, obesity-related glomerulopathy, nonalcoholic fatty liver disease, and cardiomyopathy. Insulin resistance due to lipotoxicity indirectly lead to reproductive system disorders, like polycystic ovary syndrome. Lipotoxicity has roles in insulin resistance and pancreatic beta-cell dysfunction. Increased circulating levels of lipids and the metabolic alterations in fatty acid utilization and intracellular signaling have been related to insulin resistance in muscle and liver. Different pathways, like novel protein kinase c pathways and the JNK-1 pathway, are involved as the mechanisms of how lipotoxicity leads to insulin resistance in nonadipose tissue organs, such as liver and muscle. Mitochondrial dysfunction plays a role in the pathogenesis of insulin resistance. Endoplasmic reticulum stress, through mainly increased oxidative stress, also plays an important role in the etiology of insulin resistance, especially seen in non-alcoholic fatty liver disease. Visceral adiposity and insulin resistance both increase the cardiometabolic risk, and lipotoxicity seems to play a crucial role in the pathophysiology of these associations.

Citing Articles

Risk of Insulin Resistance in 44,939 Spanish Healthcare Workers: Association with Sociodemographic Variables and Healthy Habits.

Tarraga Marcos P, Lopez-Gonzalez A, Martinez-Almoyna Rifa E, Paublini Oliveira H, Martorell Sanchez C, Tarraga Lopez P Diseases. 2025; 13(2).

PMID: 39997040 PMC: 11854469. DOI: 10.3390/diseases13020033.


Exploring the links between gallstone disease, non-alcoholic fatty liver disease, and kidney stones: A path to comprehensive prevention.

Demarquoy J World J Gastroenterol. 2025; 31(4):102452.

PMID: 39877719 PMC: 11718634. DOI: 10.3748/wjg.v31.i4.102452.


Interplay of fatty acids, insulin and exercise in vascular health.

Anderson K, Liu J, Liu Z Lipids Health Dis. 2025; 24(1):4.

PMID: 39773723 PMC: 11706162. DOI: 10.1186/s12944-024-02421-5.

References
1.
Afshinnia F, Nair V, Lin J, Rajendiran T, Soni T, Byun J . Increased lipogenesis and impaired β-oxidation predict type 2 diabetic kidney disease progression in American Indians. JCI Insight. 2019; 4(21). PMC: 6948762. DOI: 10.1172/jci.insight.130317. View

2.
Aguirre V, Uchida T, Yenush L, Davis R, White M . The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem. 2000; 275(12):9047-54. DOI: 10.1074/jbc.275.12.9047. View

3.
Ahmadian M, Duncan R, Varady K, Frasson D, Hellerstein M, Birkenfeld A . Adipose overexpression of desnutrin promotes fatty acid use and attenuates diet-induced obesity. Diabetes. 2009; 58(4):855-66. PMC: 2661591. DOI: 10.2337/db08-1644. View

4.
Anker S, Butler J, Filippatos G, Ferreira J, Bocchi E, Bohm M . Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021; 385(16):1451-1461. DOI: 10.1056/NEJMoa2107038. View

5.
Aon M, Bhatt N, Cortassa S . Mitochondrial and cellular mechanisms for managing lipid excess. Front Physiol. 2014; 5:282. PMC: 4116787. DOI: 10.3389/fphys.2014.00282. View